Notes: TAK-285 is a dual inhibitor of EGFR and HER2 (IC50s = 23 and 17 nM, respectively).{61699} It is selective for EGFR and HER2 over a panel of 36 kinases (IC50s = 250->10,000 nM). TAK-285 inhibits the proliferation of BT474 breast cancer cells (GI50 = 17 nM) as well as induces tumor regression in a 4-1st gastric adenocarcinoma rat xenograft model when administered at doses of 25 and 50 mg/kg.